Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease
The failure of several Phase II/III clinical trials in Alzheimer’s disease (AD) with drugs targeting β-amyloid accumulation in the brain fuelled an increasing interest in alternative treatments against tau pathology, including approaches targeting tau phosphatases/kinases, active and passive immuniz...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2016-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2016/3245935 |